Evaluation of the Efficacy and Safety of Intravenous Imipenem/Cilastatin/XNW4107 in Comparison With Meropenem in Hospitalized Adults With cUTI Including AP (EudraCT no. 2022-000061-40)

Complicated Urinary Tract Infection Including Acute Pyelonephritis Clinical Trial

Official title: A Multicenter, Randomized, Double-Blind, Double-Dummy, Comparative, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous Imipenem/Cilastatin/XNW4107 in Comparison With Meropenem in Hospitalized Adults With Complicated Urinary Tract Infections, Including Acute Pyelonephritis.(EudraCT no. 2022-000061-40)

Status Not yet recruiting

Clinical Trial Summary

This is A Multicenter, Randomized, Double-Blind, Double-Dummy, Comparative, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous Imipenem/Cilastatin/Funobactam in Comparison with Meropenem in Hospitalized Adults with Complicated Urinary Tract Infections, including Acute Pyelonephritis.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Complicated Urinary Tract Infection Including Acute Pyelonephritis
• Infections
• Pyelonephritis
• Urinary Tract Infections

• NCT number: NCT05204368
• Study type: Interventional
• Source: Evopoint Biosciences Inc.
• Contact: Yuanyuan Pan
• Phone: +86 0512-89162086
• Email: xnwlcyy@evopointbio.com
• Status: Not yet recruiting
• Phase: Phase 3
• Start date: March 30, 2023
• Completion date: December 2025